Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Journal of Translational Medicine

Figure 2

From: First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

Figure 2

IMP321 increases the numbers of monocytes, NK and activated CD8 T cells in blood (panel A). Fresh blood samples were collected pre-dosing, at D1, D85 and D170 and directly stained with fluorochrome-conjugated antibodies in tubes containing a precise number of fluorescent control beads. The results show the mean ± sd of the absolute numbers of CD45+CD14+ (monocytes), CD3-CD56+ (NK cells) and CD38+HLA-DR+CD8+ (activated CD8+ cells) cells. The paired non-parametric Wilcoxon signed rank test was used to compare increases observed between D85 or D170 and D1. When significant (< 0.05), p values are indicated. IMP321 increases the percentages of dendritic cells and cytotoxic CD45RA+ Effector-Memory CD8+ T cells (EMRA) in PBMCs (panel B). PBMCs cells collected pre-dosing, at D1, D85 and D170 were isolated and stained with fluorochrome-conjugated antibodies and analyzed by flow cytometry. The results show the mean ± sd of the percentages of plasmacytoid dendritic cells (pDC, CD45+CD14-CD16-HLA-DR+CD123+CD11c-) and myeloid dendritic cells (mDC, CD45+CD14-CD16-HLA-DR+CD123-CD11c+) in CD45+ cells, as well as the percentages of CD45RA+CD45RO-CD62L- in the CD8+ T cell population (CD45RA+EM CD8 T cells or EMRA). The significant Wilcoxon p values are indicated.

Back to article page